---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-015344"
form_type: "8-K"
ticker: "BIXT"
cik: "0001445815"
company_name: "BIOXYTRAN, INC"
filed_at: "2024-04-19T23:59:59+00:00"
generated_at: "2026-06-03T15:51:27.507665+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bioxytran creates insider-only convertible preferred with 10 votes per share; appoints Dr. Radka Milanova to board

## Summary
- Board designated 49.5M of 50M authorized preferred shares as Convertible Preferred Stock with 10 votes per share on as-converted basis.
- Exchange ratio: 5 common shares for 1 preferred share; conversion ratio: 1 preferred share for 5 common shares.
- Only common shares held by insiders (officers, directors) are eligible to exchange into the new preferred stock.
- Dr. Radka Milanova (PhD, Organic Chemistry) appointed to fill board vacancy left by deceased Dr. Chen-Walden.
- Dr. Milanova receives $5,000 in common stock per attended board/committee meeting; no cash compensation.

## SEC filing metadata
- accession: 0001493152-24-015344
- form_type: 8-K
- ticker: BIXT
- cik: 0001445815
- company_name: BIOXYTRAN, INC
- filed_at: 2024-04-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.03, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1445815/000149315224015344/0001493152-24-015344-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1445815/000149315224015344/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-015344
- JSON: https://secwatch.observer/filing/0001493152-24-015344.json
- Plain text: https://secwatch.observer/filing/0001493152-24-015344.txt

## Key facts
- Executive change
  Dr. Radka Milanova was elected as Director at BIOXYTRAN, INC.
  - Action: elected
  - Role: Director
  source text: Effective as of April 19, 2024, the Company has elected Dr. Radka Milanova, to fill the vacancy left by Dr. Chen-Walden, (now deceased).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1445815/000149315224015344/0001493152-24-015344-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.